Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $116.52 is 15.86% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 122.37||$ 152.55|
|Low:||$ 115.765||$ 100.57|
ETFs with UTHR as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|384%||ALPS Medical Breakthroughs ETF (SBIO)||-4.50 (-12.21%)|
|2.36%||First Trust Health Care AlphaDEX (FXH)||-0.63 (-0.85%)|
|0.73%||WisdomTree U.S. MidCap Earnings Fund (EZM)||-2.34 (-5.83%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. We market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin® (treprostinil) Injection (Remodulin); Tyvaso® (treprostinil) Inhalation Solution (Tyvaso); Orenitram® (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca® (tadalafil) Tablets (Adcirca). We also market and sell an oncology product in the United States, Unituxin® (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma. Outside the United States, our only significant revenues are derived from the sale of Remodulin, which is approved in Europe and various other countries. ... More ...
Nasdaq Official Price
Nov. 19, 2018
Nov. 19, 2018